PubRank

Adrian V Lee

Author PubWeight™ 92.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005 4.25
2 A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res 2008 4.06
3 Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008 3.74
4 Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005 3.62
5 Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 2010 3.53
6 Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009 3.36
7 Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 2007 2.48
8 AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res 2004 2.07
9 Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol 2007 1.89
10 The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 2008 1.88
11 Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003 1.74
12 Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 2005 1.58
13 Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol 2006 1.58
14 Retracted Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res 2010 1.51
15 Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 2008 1.38
16 A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 2003 1.38
17 Disruption of steroid and prolactin receptor patterning in the mammary gland correlates with a block in lobuloalveolar development. Mol Endocrinol 2002 1.37
18 Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res 2006 1.37
19 Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2008 1.34
20 The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol 2011 1.27
21 Liver-specific overexpression of the insulin-like growth factor-I enhances somatic growth and partially prevents the effects of growth hormone deficiency. Endocrinology 2006 1.25
22 Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res 2006 1.23
23 Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling. J Clin Invest 2010 1.22
24 SAFB2, a new scaffold attachment factor homolog and estrogen receptor corepressor. J Biol Chem 2003 1.22
25 Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation. Mol Cancer Res 2010 1.21
26 High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res 2010 1.20
27 Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Res 2003 1.19
28 Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J Endocrinol 2006 1.18
29 Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM. Mol Cell Biol 2009 1.15
30 Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen. FASEB J 2004 1.11
31 Structure-function analysis of the estrogen receptor alpha corepressor scaffold attachment factor-B1: identification of a potent transcriptional repression domain. J Biol Chem 2004 1.11
32 Insulin receptor substrates (IRSs) and breast tumorigenesis. J Mammary Gland Biol Neoplasia 2008 1.07
33 Scaffold attachment factor B1 functions in development, growth, and reproduction. Mol Cell Biol 2005 1.06
34 Gene expression profiling reveals novel regulation by bisphenol-A in estrogen receptor-alpha-positive human cells. Environ Res 2005 1.05
35 Crosstalk between the p190-B RhoGAP and IGF signaling pathways is required for embryonic mammary bud development. Dev Biol 2007 1.04
36 Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth. Mol Cell Endocrinol 2007 1.03
37 Insights into the role of progesterone receptors in breast cancer. J Clin Oncol 2005 1.01
38 Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2. Oncogene 2003 0.98
39 Long-range massively parallel mate pair sequencing detects distinct mutations and similar patterns of structural mutability in two breast cancer cell lines. Cancer Genet 2011 0.98
40 BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells. Clin Cancer Res 2009 0.97
41 Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat 2011 0.96
42 Local insulin-like growth factor-II mediates prolactin-induced mammary gland development. Mol Endocrinol 2002 0.96
43 Serine-derivatized gadonanotubes as magnetic nanoprobes for intracellular labeling. Contrast Media Mol Imaging 2010 0.95
44 The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 2006 0.94
45 Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med 2014 0.94
46 Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog 2012 0.92
47 Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res 2014 0.92
48 Cross talk between estrogen receptor and IGF signaling in normal mammary gland development and breast cancer. Breast Dis 2003 0.92
49 Altered mammary gland development in the p53+/m mouse, a model of accelerated aging. Dev Biol 2007 0.89
50 Decreased lactation capacity and altered milk composition in insulin receptor substrate null mice is associated with decreased maternal body mass and reduced insulin-dependent phosphorylation of mammary Akt. J Endocrinol 2007 0.89
51 Bisphenol-A and estradiol exert novel gene regulation in human MCF-7 derived breast cancer cells. Mol Cell Endocrinol 2004 0.89
52 Catalytic synthesis of amino acid and peptide derivatized gadonanotubes. J Am Chem Soc 2009 0.87
53 Parity-induced decrease in systemic growth hormone alters mammary gland signaling: a potential role in pregnancy protection from breast cancer. Cancer Prev Res (Phila) 2010 0.85
54 The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor-alpha and regulates IGF-I receptor gene transcription in breast cancer cells. J Mol Endocrinol 2005 0.85
55 Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat 2009 0.85
56 Novel role of the RET finger protein in estrogen receptor-mediated transcription in MCF-7 cells. Biochem Biophys Res Commun 2006 0.85
57 Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity. J Cell Biochem 2012 0.85
58 Disruption of scaffold attachment factor B1 leads to TBX2 up-regulation, lack of p19ARF induction, lack of senescence, and cell immortalization. Cancer Res 2006 0.85
59 Novel egg white-based 3-D cell culture system. Biotechniques 2008 0.84
60 Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2. Mol Cancer Res 2008 0.82
61 Overexpression of des(1-3) insulin-like growth factor 1 in the mammary glands of transgenic mice delays the loss of milk production with prolonged lactation. Biol Reprod 2005 0.81
62 Regulatory nodes that integrate and coordinate signaling as potential targets for breast cancer therapy. Clin Cancer Res 2004 0.81
63 Developing in vitro models of human ductal carcinoma in situ from primary tissue explants. Breast Cancer Res Treat 2015 0.80
64 Who's driving anyway? Herculean efforts to identify the drivers of breast cancer. Breast Cancer Res 2012 0.79
65 A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis. BMC Cancer 2011 0.79
66 Is it time to ReSET the standard for estrogen receptor testing in breast cancer? J Clin Oncol 2010 0.79
67 Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res 2006 0.79
68 The evolving role of multi-gene tests in breast cancer management. Oncology (Williston Park) 2013 0.77
69 Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res 2004 0.77
70 Analysis of interactions between the epigenome and structural mutability of the genome using Genboree Workbench tools. BMC Bioinformatics 2014 0.76
71 Scaffold Attachment Factor B1 (SAFB1) heterozygosity does not influence Wnt-1 or DMBA-induced tumorigenesis. Mol Cancer 2009 0.75
72 Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 2020 0.75
73 Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer. Appl Immunohistochem Mol Morphol 2016 0.75
74 Inability of Overexpressed des(1-3)Human Insulin-Like Growth Factor I (IGF-I) to Inhibit Forced Mammary Gland Involution Is Associated with Decreased Expression of IGF Signaling Molecules. Endocrinology 2001 0.75
75 Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators? Nat Clin Pract Oncol 2006 0.75
76 Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clin Cancer Res 2003 0.75